FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000817712> ?p ?o ?g. }

• W2000817712 endingPage "425" @default.
• W2000817712 startingPage "420" @default.
• W2000817712 abstract "For the patient-administered treatment of anogenital warts, 0.5% podofilox (podophyllotoxin), one of the active compounds of podophyllin, has been shown to be more effective than the vehicle alone. This study was designed to evaluate the safety and efficacy of 0.5% podofilox treatment followed by prophylaxis.A total of 103 patients were entered in stage 1 of the study. Stage 1 was an open label study, and patients self-administered 0.5% podofilox twice daily for 3 consecutive days per week for 4 weeks. A total of 100 patients remained available for efficacy and safety analyses. At the end of stage 1, patients who had a complete response proceeded to stage 2 of the study. Patients who had a 50% to 99% reduction in measured total wart area were offered cryotherapy every 10 days, up to 5 times. If cleared of warts, they were also entered into stage 2. A total of 57 patients were enrolled into stage 2, a double-blind, randomized, placebo-controlled prophylactic study of 0.5% podofilox self-administered once daily for 3 days per week for 8 weeks, on the sites of healed warts. A total of 45 patients in stage 2 were available for efficacy analysis.By the end of stage 1, 68% of the warts had disappeared, and 29 of 100 patients (29%) had a complete response. A total of 49 patients had a 50% or greater improvement in wart area and underwent cryotherapy. Rates of local side effects after 1 week of treatment were 57% for inflammation, 39% for erosion, 47% for pain, 48% for burning, and 44% for itching. However, these symptoms and signs were mostly mild to moderate in intensity and diminished over time. Therefore, overall treatment was well tolerated. In stage 2, only 4 of 21 patients (19%) in the podofilox group experienced a recurrence as opposed to 12 of 24 (50%) in the placebo group (P = 0.031). As in stage 1, the side effects were modest, and the drug was well tolerated.This study confirms the efficacy and good tolerance of 0.5% podofilox in the treatment of anogenital warts. It also establishes the safety and superior efficacy of patient-administered podofilox over the vehicle alone as prophylaxis against recurrence of lesions. Although long-term efficacy and tolerance remain to be established, podofilox appears to be a useful agent in the control of this disease." @default.
• W2000817712 created "2016-06-24" @default.
• W2000817712 creator A5031268451 @default.
• W2000817712 creator A5033700440 @default.
• W2000817712 creator A5034346062 @default.
• W2000817712 creator A5036045574 @default.
• W2000817712 creator A5037831362 @default.
• W2000817712 creator A5040054103 @default.
• W2000817712 creator A5058641567 @default.
• W2000817712 creator A5077487071 @default.
• W2000817712 date "1994-05-01" @default.
• W2000817712 modified "2023-10-06" @default.
• W2000817712 title "Efficacy and safety of 0.5% podofilox solution in the treatment and suppression of anogenital warts" @default.
• W2000817712 cites W2021188301 @default.
• W2000817712 cites W2071379551 @default.
• W2000817712 cites W2102120234 @default.
• W2000817712 cites W2336884743 @default.
• W2000817712 cites W4245766958 @default.
• W2000817712 cites W4321001268 @default.
• W2000817712 doi "https://doi.org/10.1016/0002-9343(94)90168-6" @default.
• W2000817712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8192173" @default.
• W2000817712 hasPublicationYear "1994" @default.
• W2000817712 type Work @default.
• W2000817712 sameAs 2000817712 @default.
• W2000817712 citedByCount "49" @default.
• W2000817712 countsByYear W20008177122012 @default.
• W2000817712 countsByYear W20008177122013 @default.
• W2000817712 countsByYear W20008177122014 @default.
• W2000817712 countsByYear W20008177122015 @default.
• W2000817712 countsByYear W20008177122016 @default.
• W2000817712 countsByYear W20008177122017 @default.
• W2000817712 countsByYear W20008177122019 @default.
• W2000817712 countsByYear W20008177122020 @default.
• W2000817712 crossrefType "journal-article" @default.
• W2000817712 hasAuthorship W2000817712A5031268451 @default.
• W2000817712 hasAuthorship W2000817712A5033700440 @default.
• W2000817712 hasAuthorship W2000817712A5034346062 @default.
• W2000817712 hasAuthorship W2000817712A5036045574 @default.
• W2000817712 hasAuthorship W2000817712A5037831362 @default.
• W2000817712 hasAuthorship W2000817712A5040054103 @default.
• W2000817712 hasAuthorship W2000817712A5058641567 @default.
• W2000817712 hasAuthorship W2000817712A5077487071 @default.
• W2000817712 hasConcept C121608353 @default.
• W2000817712 hasConcept C126322002 @default.
• W2000817712 hasConcept C126894567 @default.
• W2000817712 hasConcept C138944611 @default.
• W2000817712 hasConcept C141071460 @default.
• W2000817712 hasConcept C142724271 @default.
• W2000817712 hasConcept C146357865 @default.
• W2000817712 hasConcept C151730666 @default.
• W2000817712 hasConcept C168563851 @default.
• W2000817712 hasConcept C185592680 @default.
• W2000817712 hasConcept C204787440 @default.
• W2000817712 hasConcept C27081682 @default.
• W2000817712 hasConcept C2778143360 @default.
• W2000817712 hasConcept C2778220009 @default.
• W2000817712 hasConcept C2778308922 @default.
• W2000817712 hasConcept C2779136573 @default.
• W2000817712 hasConcept C2780149145 @default.
• W2000817712 hasConcept C2910107953 @default.
• W2000817712 hasConcept C2994532551 @default.
• W2000817712 hasConcept C71240020 @default.
• W2000817712 hasConcept C71924100 @default.
• W2000817712 hasConcept C86803240 @default.
• W2000817712 hasConceptScore W2000817712C121608353 @default.
• W2000817712 hasConceptScore W2000817712C126322002 @default.
• W2000817712 hasConceptScore W2000817712C126894567 @default.
• W2000817712 hasConceptScore W2000817712C138944611 @default.
• W2000817712 hasConceptScore W2000817712C141071460 @default.
• W2000817712 hasConceptScore W2000817712C142724271 @default.
• W2000817712 hasConceptScore W2000817712C146357865 @default.
• W2000817712 hasConceptScore W2000817712C151730666 @default.
• W2000817712 hasConceptScore W2000817712C168563851 @default.
• W2000817712 hasConceptScore W2000817712C185592680 @default.
• W2000817712 hasConceptScore W2000817712C204787440 @default.
• W2000817712 hasConceptScore W2000817712C27081682 @default.
• W2000817712 hasConceptScore W2000817712C2778143360 @default.
• W2000817712 hasConceptScore W2000817712C2778220009 @default.
• W2000817712 hasConceptScore W2000817712C2778308922 @default.
• W2000817712 hasConceptScore W2000817712C2779136573 @default.
• W2000817712 hasConceptScore W2000817712C2780149145 @default.
• W2000817712 hasConceptScore W2000817712C2910107953 @default.
• W2000817712 hasConceptScore W2000817712C2994532551 @default.
• W2000817712 hasConceptScore W2000817712C71240020 @default.
• W2000817712 hasConceptScore W2000817712C71924100 @default.
• W2000817712 hasConceptScore W2000817712C86803240 @default.
• W2000817712 hasIssue "5" @default.
• W2000817712 hasLocation W20008177121 @default.
• W2000817712 hasLocation W20008177122 @default.
• W2000817712 hasOpenAccess W2000817712 @default.
• W2000817712 hasPrimaryLocation W20008177121 @default.
• W2000817712 hasRelatedWork W1985964291 @default.
• W2000817712 hasRelatedWork W2000817712 @default.
• W2000817712 hasRelatedWork W2003086496 @default.
• W2000817712 hasRelatedWork W2053006773 @default.
• W2000817712 hasRelatedWork W2136629536 @default.
• W2000817712 hasRelatedWork W2188537392 @default.
• W2000817712 hasRelatedWork W3002272325 @default.

• next